company background image
SNPX

Synaptogenix NasdaqCM:SNPX Stock Report

Last Price

US$6.89

Market Cap

US$47.1m

7D

-3.5%

1Y

-26.9%

Updated

27 Sep, 2022

Data

Company Financials +
SNPX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SNPX Stock Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development.

Synaptogenix, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Synaptogenix
Historical stock prices
Current Share PriceUS$6.89
52 Week HighUS$14.50
52 Week LowUS$3.79
Beta0
1 Month Change-17.98%
3 Month Change32.25%
1 Year Change-26.86%
3 Year Changen/a
5 Year Changen/a
Change since IPO100.29%

Recent News & Updates

Sep 20
We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth

We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

May 10
Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Nov 17

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer’s Disease in moderately severe to severe patients. Post-hoc analysis of 95 patients from these two studies with MMSE 10-15, and not taking Namenda, revealed a statistically significant improvement vs placebo. Based on learnings from the first two trials, a third trial is underway with a longer duration (6 vs 3 months) and a narrowed patient population – read-out targeted for 2H2022. The probability of success in the current trial is reasonable based on the learnings from the first two trials, but the small size is a risk that a statistically-significant improvement may not be achieved. The potential large upside affords a highly positive asymmetric risk-reward.

Shareholder Returns

SNPXUS BiotechsUS Market
7D-3.5%-3.3%-5.8%
1Y-26.9%-27.4%-22.1%

Return vs Industry: SNPX exceeded the US Biotechs industry which returned -30.6% over the past year.

Return vs Market: SNPX underperformed the US Market which returned -23.7% over the past year.

Price Volatility

Is SNPX's price volatile compared to industry and market?
SNPX volatility
SNPX Average Weekly Movement10.1%
Biotechs Industry Average Movement11.0%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: SNPX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: SNPX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20124Alan Tuchmanhttps://www.synaptogen.com

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

Synaptogenix, Inc. Fundamentals Summary

How do Synaptogenix's earnings and revenue compare to its market cap?
SNPX fundamental statistics
Market CapUS$47.13m
Earnings (TTM)-US$14.19m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SNPX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$14.19m
Earnings-US$14.19m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.07
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did SNPX perform over the long term?

See historical performance and comparison